Linked videos:
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
Sources:
1. MarketScreener. Kintor Pharmaceutical Limited Announces Phase Ib/III Clinical Trial of KX-826 and Minoxidil Combination Therapy for the Treatment of Men Adults Receives Clearance by China NMPA -February 01, 2024 at 03:46 am EST | MarketScreener. Published February 1, 2024. Accessed February 29, 2024. [ Ссылка ]
2. Suzhou Kintor Pharmaceutical Inc,. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Male Subjects With Androgenetic Alopecia to Evaluate the Safety, Tolerability and PK of KX-826 Following Topical Multiple Dose Ascending. clinicaltrials.gov; 2021. Accessed April 11, 2021. [ Ссылка ]
3. Clinical Trial on Androgenetic Alopecia: KX0826, Placebo - Clinical Trials Registry - ICH GCP. Accessed April 12, 2021. [ Ссылка ]
4. Pharma K. Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China. Accessed March 4, 2024. [ Ссылка ]
5. Glaser R, Dimitrakakis C, Messenger A. Improvement in scalp hair growth in androgen-deficient women treated with testosterone: a questionnaire study. Br J Dermatol. 2012;166(2):274-278. doi:10.1111/j.1365-2133.2011.10655.x
